# Legal Review — AGRI NUTRITION AND PHARMA PVT. LTD. (Nepal)

*Advisory analysis only. Not a substitute for licensed Indonesian / Nepali legal counsel — review with internal legal before signing or acting.*

**Counterparty:** AGRI NUTRITION AND PHARMA PVT. LTD., Kathmandu, Nepal
**JAPFA principal:** PT Vaksindo Satwa Nusantara (Indonesian exporter)
**Agreement type:** Distributorship Agreement
**Effective Date:** 31 March 2023
**Termination Date (stated):** 30 March 2026 (3-year term)
**Status today (14 May 2026):** **EXPIRED 45 days ago — operating without paper**
**LOA expiry:** 30 March 2026 (also EXPIRED)
**Governing law:** Republic of Indonesia
**Dispute resolution:** BANI **or** SIAC Rules (Art. 34.2) — **broken dual-track**
**Signed by:** Dr. Teguh Yodiantara Prajitno (President Director, Vaksindo) and Suresh Vaidya (Director, Agri Nutrition) — **neither party dated their signature**

---

## Executive summary — what this contract really is

This is a clean Vaksindo template distribution agreement for an 8-SKU veterinary vaccine deal in Nepal. The commercial substance is workable: clear pricing (CIF Kathmandu), LC 45-day payment, 12-month shelf life floor, MA registered in the distributor's name but legally held as a **bailee** for Vaksindo (Art. 4.2), and a non-exclusive appointment. Schedule A targets are modest at ~14,500 units year 1 / 17,200 year 2 (1000-dose vials) with a 20% annual uplift.

There are **three problems that drag this contract down hard right now**:

1. **It expired 45 days ago.** Both the Distribution Agreement and the LOA terminated on 30 March 2026. If Vaksindo and Agri Nutrition are still shipping and paying, they are doing it **on bare PO mechanics, with no contractual rights or remedies behind them.** The 12-month sell-off right under Art. 24.2 is also already running.
2. **Dual-track dispute clause that doesn't actually work.** Art. 34.2 says disputes go to "BANI **or** in accordance with the SIAC Rules". That "or" is fatal — neither side can compel the other into a single forum. This is the same pathological clause the rebalanced rubric flags as -10.
3. **Territorial overlap with the Kantipur Vet contract.** Vaksindo also signed a 3-year distributorship with Kantipur Vet Distributors Pvt. Ltd. (effective 1 Jan 2024) covering the same Nepal territory and overlapping products. Kantipur's agreement **converts to EXCLUSIVE on 1 Jan 2025 if Kantipur hit its first-year targets**. If that trigger fired, Vaksindo had two-distributor exposure throughout Q1 2025–Q1 2026 — a contractual exposure Vaksindo needs to verify with the Kantipur sales record.

Liability is capped at 1 month of purchases (Art. 21.4) — that's the rubric's standard penalty. KUHPerdata Art. 1266/1267 waiver is missing. Sanctions / Bahasa items are info-only per JAPFA's outbound concern profile.

**Verdict:** **Negotiate before signing** the renewal. **C-band score** — acceptable historic contract but the expired status + dual-forum clause + Kantipur conflict means JAPFA cannot ride it into a fourth year. The renewal is the moment to fix three things and clarify the Nepal strategy.

---

## Score: 64 / 100 — Grade C

**Verdict:** negotiate material — fix the dispute clause, fix the multi-distributor wording, and execute a renewal before further shipments.
**Confidence:** High (full 17-page agreement readable; 2-page LOA readable; cross-checked Kantipur agreement first 5 pages + Schedule A).

### Section breakdown

| # | Section | Score | Weight | Rationale |
|---|---------|-------|--------|-----------|
| 1 | Territory, exclusivity & multi-distributor permissibility | 7 / 12 | 12 | Explicitly NON-EXCLUSIVE (Art. 5) — good for JAPFA flexibility. **But** territorial overlap risk with Kantipur (whose contract may now be exclusive). "Can JAPFA appoint a second distributor?" YES under this contract — already done. The unknown is whether Kantipur's exclusivity trigger fired. |
| 2 | Pricing, payment & FX | 7 / 10 | 10 | CIF Kathmandu Airport (Art. 3.1); annual mutual price revision (3.2); LC 45-day acceptable bank (Art. 9.1) — solid. No FX clause for NPR/USD or Nepal Rastra Bank 180-day repatriation reference — minor info-only gap. |
| 3 | Time-tiered discounts & rebates | 3 / 6 | 6 | Silent. No volume-tier discount mechanism. 20% upward target revision (Schedule A) is the only escalator — works in JAPFA's favor. |
| 4 | Sales targets & minimums | 5 / 8 | 8 | Schedule A quantitative; Art. 7.2 enforceable "pay-for-shortfall OR terminate" — good. Art. 18.3 "if no agreement on next year forecast by Oct 31, Supplier appoints third party as distributor" — strong JAPFA exit lever. |
| 5 | Termination, post-term & counterparty-country termination compensation | 6 / 14 | 14 | KUHPerdata Art. 1266/1267 waiver missing (-3). Contract expired 45 days ago and parties may still be performing (-5). 12-month sell-off period (Art. 24.2) is generous but already mid-clock. Nepal does **not** have agency-law mandatory termination compensation per country notes — so no Saudi/UAE/Egypt-style overhang. MA transfer-back (Art. 24.3-24.4) is solid: distributor must transfer or surrender at termination. |
| 6 | Registration / MA / NIE ownership & practical recoverability | 9 / 12 | 12 | Art. 4.2: registration "at all times owned by Supplier, even if held in name of Distributor" — distributor is "**bailee**" (caretaker) to Supplier's registration. Strong language. Art. 4.5: distributor "shall surrender usage rights to Supplier without any cost" at termination. Art. 24.3-24.5: free-of-cost transfer obligation. **One weak point**: no specific deadline / cooperation timeline for the DDA Nepal transfer-back process — typically 60-90 days but the contract is silent. |
| 7 | International dispute & enforceability in counterparty country | 5 / 14 | 14 | **PATHOLOGICAL dual-track**: Art. 34.2 reads "the Parties agree to bring the dispute to BANI **or** in accordance with the SIAC Rules" (-10). Either party can refuse the other's choice and stalemate. Nepal IS a NY Convention signatory (acceded 1998) — so a clean SIAC award would be enforceable in Kathmandu commercial bench. But this clause cannot produce a clean award until amended. Plus the 30-business-day good-faith negotiation precondition (34.2) is reasonable. |
| 8 | IP, confidentiality & non-compete | 5 / 6 | 6 | Strong: Art. 6 Competing Products non-compete during term; Art. 10-11 trademark + IP licensing tight; Art. 16.6 5-year confidentiality survival post-termination (+1). |
| 9 | Liability, indemnity & compliance reps (sanctions/Bahasa excluded) | 5 / 8 | 8 | Art. 21.4: 1-month-of-purchases liability cap (-6 in standard schedule, but partly offset by Art. 21.1 distributor-side indemnification being broad and Art. 21.3 consequential damages exclusion). Art. 25 has anti-bribery / no-forced-labor / no-child-labor language — modest but present. Sanctions reps missing: info-only per concern profile, no deduction. |
| 10 | Counterparty-country voidance risks & misc boilerplate | 7 / 10 | 10 | Nepal-specific items: **Stamp Act 2019** may apply to commercial agreements — verify with Nepali counsel. **Language**: Nepali required for state-court evidence — contract is English-only, which is fine for arbitration but is a risk if it ever ends up in Kathmandu District Court. **Nepal Rastra Bank** FX repatriation 180-day rule: not addressed but governs distributor's USD outflow to Vaksindo. Force majeure (Art. 28) reasonable. Hague Apostille: Nepal is **not** a member — consular legalization required for any cross-border evidence. |
| | **Total** | **59 / 100** | | Re-weighted +5 positive credit (Indonesian governing law preserved +3; MA bailee construction +3 — partial because no transfer-back timeline; SIAC referenced in some form even though broken +1; 5-year confidentiality survival +1; minus 1 for undated signatures + missing 1266/1267 waiver double-count adjustment) = **64 / 100** |

### Score drivers

**Largest negative drivers**
- **Section 7 — Dispute clause is dual-track unworkable** (-10): Art. 34.2 "BANI or SIAC Rules" can't be compelled. Either side can stall a dispute indefinitely on forum selection. Benchmark says single-clause SIAC Singapore is the JAPFA-favorable target.
- **Section 5 — Contract expired with parties still performing** (-5): 30 March 2026 was 6 weeks ago. Any shipment since then has no contractual basis. Damages would have to be litigated on quasi-contract grounds in either Indonesia or Nepal, with no clear forum.
- **Section 9 — 1-month liability cap** (-3 here, capped per rubric): Art. 21.4 caps Supplier liability at the purchase price of products bought "for a period of 1 (one) month immediately preceding any breach". For a slow-burn registration-loss claim, that is functionally near-zero coverage for Agri Nutrition.

**Largest positive drivers**
- **Section 6 — MA bailee construction** (+3): Art. 4.2 keeps regulatory ownership with Vaksindo even when registration is in Agri Nutrition's name. Strongest JAPFA-favorable clause in the document.
- **Section 1 — Explicit non-exclusivity** (+3): Art. 5 gives JAPFA the right to appoint a second distributor (already exercised — Kantipur).
- **Section 8 — 5-year confidentiality survival** (+1): Art. 16.6 — standard but valuable post-termination.
- **Section 4 — Pre-Oct-31 third-party-distributor exit lever** (+2): Art. 18.3 lets Supplier walk if next-year targets can't be agreed by Oct 31. Useful in negotiations.

### Score trajectory if negotiated

- If JAPFA wins the top 3 negotiation priorities (single SIAC clause + KUHPerdata waiver + clear renewal with Kantipur carve-out): **~80 / 100 (Grade B)**.
- If JAPFA accepts the current draft as-is into a renewal: **64 / 100 (Grade C)** — same as today.
- Ceiling if JAPFA wins everything (above plus 12-month minimum liability cap + Nepal-specific FX/language/stamping addressed): **~86 / 100 (Grade A-)**.

Traffic light: **AMBER**.

---

## Critical risks — 3 numbered, with plain-language and what-to-do blocks

### 1. CRITICAL — Contract and LOA both expired 45 days ago; parties may still be shipping

**What the contract says:** Art. 23.1 — *"This Agreement shall commence and remain in force for about 3 (three) years from the Effective Date and will be terminated on 30 March 2026, unless terminated earlier as stated herein."* The LOA dated 27 March 2023 states *"This letter shall be valid until March 30th 2026."*

**Plain English:** Today is 14 May 2026. The paper that lets Agri Nutrition act as our distributor and hold our DDA Nepal registration legally ended 6 weeks ago. Until we either sign a renewal or notify Agri Nutrition that we're terminating, every shipment we send, every payment they make, and every product they sell in Nepal is happening on the basis of a phone call and old habit — not a contract. If a quality complaint hits next month, neither side has a clear set of rights to point to. Worse, our 12-month sell-off window in Art. 24.2 is already running, and the DDA registration — which is in Agri Nutrition's name as our bailee — sits in legal limbo. If Agri Nutrition decides today to assert rights against the registration, our case in Kathmandu just got harder.

**What you should do:**
- **Day 0–7 (this week):** Email Suresh Vaidya at suresh@ccu.com.np with cc to Dr. Teguh, stating that the agreement has expired and Vaksindo is treating shipments since 30 March 2026 as "interim arrangement pending renewal" — preserves position without breaching.
- **Day 0–14:** Internal call with Vaksindo export desk + Pak Yusman: decide is the Nepal strategy (a) renew Agri Nutrition, (b) consolidate behind Kantipur, or (c) keep both with carve-outs?
- **Day 14–30:** If renewing, send renewal draft using fixed dispute clause (single SIAC Singapore, see below) + KUHPerdata 1266/1267 waiver + explicit Kantipur carve-out language. Use the Kantipur template structure (3-year with year-1 non-exclusive → conversion to exclusive) only if you want to give Agri Nutrition that path.
- **Day 30–60:** Execute renewal AND a new LOA. Replace both pieces of paper. Reset the 12-month sell-off clock.

---

### 2. CRITICAL — Dispute clause is dual-track and cannot be enforced as written

**What the contract says:** Art. 34.2 — *"Any dispute arising between the Parties in relation with this Agreement, shall be settled among the Parties in good faith within thirty (30) business days since the date of the dispute. Failing that, the Parties agree to bring the dispute to BANI (Badan Arbitrase Nasional Indonesia) **or** in accordance with the arbitration rules of the Singapore International Arbitration Centre ('SIAC Rules')."*

**Plain English:** This is a broken clause. You and Agri Nutrition have agreed that disputes go either to BANI (the Indonesian arbitration institution in Jakarta) **or** to SIAC (the Singapore arbitration institution) — and there is no rule for choosing. If a dispute happens, neither party can force the other into a forum. The likely real-world outcome: Vaksindo files in SIAC, Agri Nutrition resists and counter-files in BANI (or worse, in a Kathmandu commercial court), and the next 12 months get spent arguing about where to argue — not about the merits. Nepal IS a New York Convention signatory (the global treaty that makes arbitration awards enforceable across borders), so a clean SIAC Singapore award **would** be enforceable in a Kathmandu commercial bench — but only if the seat is clean to begin with.

**What you should do:**
- **At renewal:** Replace Art. 34.2 entirely with this single sentence: *"Any dispute, controversy, or claim arising out of or relating to this Agreement, including its existence, validity, interpretation, performance, breach or termination, shall be referred to and finally resolved by arbitration administered by the Singapore International Arbitration Centre in accordance with the SIAC Rules in force at the time. The seat of arbitration shall be Singapore. The tribunal shall consist of one arbitrator. The language of arbitration shall be English."*
- **Keep** the 30-business-day good-faith negotiation precondition — that part works.
- **Do NOT** offer BANI as an alternative. Nepal is far closer to Singapore commercially and SIAC awards enforce easily under NY Convention 1958. BANI awards are also enforceable in Nepal under NY Convention but BANI's case-management speed is materially slower and Nepali counsel are far less familiar with Indonesian arbitration.

---

### 3. CRITICAL — Multi-distributor conflict risk with Kantipur Vet (the other Nepal distributor)

**What the contracts say:**
- This contract (Agri Nutrition, Art. 5): NON-EXCLUSIVE first year then silent — operationally treated as non-exclusive throughout.
- Kantipur Vet Distribution Agreement (separate file, effective 1 Jan 2024, signed 35-03-2024 BS = 17 June 2024 AD): NON-EXCLUSIVE first year → *"conditional upon Distributor achieving the specified targets in Schedule A during the Initial Period and is limited to the Products specified therein. The achievement of these targets and subsequent transition to exclusivity will be subject to a formal review on 1st January 2025."*

**Plain English:** Vaksindo has two Nepal distributors. The Kantipur contract has a switch baked in — if Kantipur hit its 2024 sales targets, then on **1 January 2025** Kantipur's status flipped to **EXCLUSIVE** for the listed Schedule A products. We need to confirm: did Kantipur hit the target, and did the conversion happen? Because if yes, then from 1 Jan 2025 onward, Vaksindo had a contract with Agri Nutrition for the same products at the same time. Agri Nutrition's contract was non-exclusive so Vaksindo isn't in breach of Agri Nutrition — but Vaksindo COULD be in breach of Kantipur for continuing to supply Agri Nutrition. The exposure is roughly 15 months of dual supply (Jan 2025 to today) on overlapping SKUs: Vaksimune NDLS, IBD D, IBD M+, Pox, ND L Inaktif, Coryza LE, ND L IBPlus.

**What you should do:**
- **Day 0–7:** Pak Yusman to pull Kantipur 2024 Jan–Dec actuals against Kantipur's Schedule A. If Kantipur missed targets, conversion did not fire — risk drops to LOW.
- **Day 7–14:** If Kantipur hit targets, draft a written acknowledgement to Kantipur explaining the Agri Nutrition contract was pre-existing, was non-exclusive, has now expired, and ask Kantipur to confirm in writing that they do not consider Vaksindo in breach.
- **Day 14–30:** If renewing Agri Nutrition, the renewal MUST contain an explicit carve-out: *"Distributor acknowledges that Supplier has appointed an additional distributor in the Territory and that this Agreement is non-exclusive. Distributor shall not pursue or assert any claim against Supplier on grounds of competing appointment in the Territory."* Same for any Kantipur renewal — both contracts must reference each other.
- **Day 0 onward:** Country notes confirm Nepal Contract Act 2056 (2000) does NOT impose mandatory exclusivity or compensation. So this is a contract-level issue, not a Nepali statutory exposure.

---

## High-priority items

### 4. HIGH — 1-month liability cap (Art. 21.4) — extreme low

**What the contract says:** *"Supplier's liability under this Agreement or for the termination of this Agreement will not, in any event, exceed the purchase price of the products purchased by Distributor for a period of 1 (one) month immediately preceding any breach of contract."*

**Plain English:** If Vaksindo breaches the contract — say a vaccine batch is contaminated, or we lose the DDA registration because we delayed Dossier updates — our maximum payout to Agri Nutrition is one month of their purchases from us. At Schedule A run rate, that's roughly USD 20,000–25,000. Real-world claim from a vaccine quality failure that wipes out poultry flocks in Nepal could be USD 200,000+ on direct loss alone. We are exposed to brand and ongoing-relationship risk that hugely exceeds this cap. From Vaksindo's perspective the cap is a positive — it protects the supplier — but it's so aggressive that Agri Nutrition would normally have pushed back. The fact that they didn't suggests they didn't read it carefully, which is a fragility for the relationship.

**What you should do:** At renewal, offer to move to 12 months of purchases as a compromise. It still protects Vaksindo from runaway damages, but signals fairness. If Agri Nutrition asks for "actual direct damages capped at insurance proceeds" — that's fine too.

---

### 5. HIGH — KUHPerdata Art. 1266 / 1267 waiver missing

**What the contract says:** Nothing. Art. 23 covers termination grounds but doesn't reference KUHPerdata.

**Plain English:** Indonesian governing law applies (Art. 34.1). Under Indonesian Civil Code Article 1266, you cannot simply terminate a reciprocal contract by giving notice — you have to go to court first and ask a judge for permission to terminate. Article 1267 then gives the other side a parallel right to demand performance instead of termination. JAPFA / Vaksindo can wipe this requirement out by inserting a one-line waiver. Without the waiver, **any unilateral termination by Vaksindo** under Art. 23.2(a)-(f) **could theoretically be challenged in an Indonesian court as not yet effective until a judge confirms it.** In practice with foreign distributors it's rare to litigate KUHPerdata 1266 — but the waiver is free and standard.

**What you should do:** At renewal, add this single sentence to Art. 23 or as a new Art. 23.4: *"The Parties hereby waive the application of Article 1266 and Article 1267 of the Indonesian Civil Code (KUHPerdata) such that no prior court order or judgement shall be required to give effect to any termination or rescission of this Agreement undertaken in accordance with its terms."*

---

### 6. HIGH — MA transfer-back has no timeline or DDA-specific cooperation language

**What the contract says:** Art. 24.3 — Distributor "shall file an application before the Regulatory Authorities in the Territory to withdraw its name as the registration holder" + Art. 4.5 "Distributor shall surrender usage rights to Supplier without any cost".

**Plain English:** The good news is that the contract is clear that the **marketing authorisation (MA — the DDA Nepal regulatory permit to sell each vaccine)** legally belongs to Vaksindo even though it's registered in Agri Nutrition's name. So Vaksindo can demand a transfer at termination. The bad news is the contract doesn't say HOW FAST. The DDA Nepal transfer-back process typically takes 60-90 days with full distributor cooperation — and can take 6-12 months without cooperation, during which Vaksindo cannot legally market in Nepal under a new distributor. For a vaccine business that means lost flocks and lost revenue. Missing market access for 6+ months is the most economically painful exposure in any vet distribution termination.

**What you should do:** At renewal, add to Art. 24.3: *"Distributor shall complete and submit all required DDA Nepal forms, dossier transfer letters, and authorisation withdrawals within 30 (thirty) calendar days of termination or expiry, and shall provide reasonable cooperation thereafter to facilitate Supplier's appointment of a successor distributor. Any delay attributable to Distributor's non-cooperation entitles Supplier to liquidated damages of USD [X] per calendar day, capped at USD [Y]."*

---

## Compliance — 4-question framework

### Q1: Is the contract valid and enforceable in Indonesia (the governing-law jurisdiction)?

**Mostly yes, with two cure items.** Indonesian governing law is preserved (Art. 34.1) — clean. Contract is in English; UU 24/2009 Bahasa Indonesia bilingual requirement is **info-only** for Vaksindo (the Indonesian outbound side cannot have UU 24/2009 invoked against it by a foreign court, and Vaksindo will not invoke it against itself). The two cures: missing KUHPerdata 1266/1267 waiver (item 5 above) and the dual-track dispute clause (item 2 above). The Bea Meterai stamp duty is informational only — no formal validity impact if missing. **Verdict: enforceable in Indonesia subject to the dispute clause fix.**

### Q2: Is the contract enforceable in Nepal (where assets and the distributor sit)?

**Likely yes, with caveats.** Nepal acceded to the **New York Convention 1958** (the global treaty making arbitration awards enforceable across borders) on 4 June 1998, with reciprocity reservation. A clean SIAC Singapore arbitration award would be enforceable through Nepal's Arbitration Act 2055 (1999) at the High Court / Patan High Court commercial bench. Current dispute clause defect (item 2) blocks this — fix it. **Stamp Act**: Nepal's Stamp Act 2019 BS imposes nominal stamping on commercial agreements; verify with Nepali counsel whether this contract should have been stamped on Nepal-side execution. **Language**: Nepali is required for state-court evidence — but if disputes route to SIAC instead, this is not a live issue. **Hague Apostille**: Nepal is NOT a member, so any document used in Nepali court needs consular legalization — keep this in mind for evidence handling. **Verdict: enforceable via SIAC once dispute clause is fixed; would have problems in Nepali state court.**

### Q3: Are there sanctions, anti-bribery, or counterparty integrity issues?

**No live exposure.** Per JAPFA outbound concern profile, sanctions reps missing is INFO-only and does not cost points. JAPFA compliance has cleared Agri Nutrition. Nepal is not under blanket sanctions (OFAC, EU, UN). The contract has clean anti-bribery language at Art. 25 ("Any practice of corruption, extortion and embezzlement are prohibited. Distributor shall not pay or accept bribes…"). No-forced-labor / no-child-labor reps in Art. 25.2. **Verdict: clean.**

### Q4: Are JAPFA's regulatory commitments operationally workable?

**Mostly yes.** Vaksindo Indonesia-side: Indonesian GMP referenced (Art. 13.1) — workable. Vaccine shelf life floor 12 months (Art. 13.1) — standard, workable. QC certificate per shipment (Art. 13.1) — standard. **Pharmacovigilance** (Art. 26) is mentioned but not detailed — Nepal DDA pharmacovigilance reporting timelines should be addressed in a side-letter or schedule. **Adverse event reporting** (Art. 13.6) timing: distributor reports to Supplier within 10 calendar days — borderline acceptable; rubric flags >5 days as a -2. **Verdict: operational, minor pharmacovigilance gap.**

---

## Compliance checklist — Nepal-specific

| Item | Status | Action |
|------|--------|--------|
| DDA Nepal vaccine registration (Department of Drug Administration, dda.gov.np) | Held in distributor's name as Vaksindo's bailee per Art. 4.2 | Verify renewal status of each of 8 Schedule A SKUs with DDA |
| Nepal Rastra Bank — 180-day FX repatriation rule | Not addressed in contract | Confirm Agri Nutrition has remitted all 2025/2026 USD payments to Vaksindo within the 180-day window |
| Nepal Stamp Act 2019 BS | Unknown if stamped Nepal-side | Ask Nepali counsel; if not stamped, instrument is theoretically inadmissible in Nepali court until stamped + penalty |
| Nepal Contract Act 2056 (2000) — multi-distributor permissibility | No statutory ban on multiple distributors | Continue both Kantipur and Agri Nutrition appointments; document non-exclusivity in writing |
| Hague Apostille | Nepal is NOT a member | Use consular legalization (Embassy of Nepal in Jakarta) if Nepali-court evidence is needed |
| NY Convention 1958 | Nepal acceded 4 June 1998 (with reciprocity reservation) | SIAC Singapore awards enforceable in Nepal — but fix the dispute clause first |
| Pharmacovigilance — Nepal DDA reporting | Mentioned in Art. 26 but no detail | Add a side-letter specifying DDA pharmacovigilance reporting workflow |
| Tax — Nepal withholding on imports / royalty | Not addressed | Confirm with internal tax: any Nepal withholding tax on vaccine imports CIF? |

---

## Top negotiation moves (at renewal)

| # | Move | Negotiability | What to ask for | Fallback |
|---|------|---------------|-----------------|----------|
| 1 | Fix dispute clause to single SIAC Singapore | HIGH | One paragraph rewrite, Singapore seat, English language, single arbitrator | If counterparty wants BANI: keep SIAC, add explicit BANI exclusion |
| 2 | Add KUHPerdata 1266/1267 waiver | HIGH | One sentence in Art. 23 | Frame as housekeeping; no commercial cost to counterparty |
| 3 | Explicit Kantipur carve-out (non-exclusivity + Vaksindo right to appoint additional) | HIGH | Plain language acknowledgement | If Agri Nutrition resists, offer them 90-day exclusive sub-territory on 1-2 SKUs |
| 4 | MA transfer-back 30-day deadline + per-day liquidated damages | MEDIUM | 30 days + cap at USD 50K | Frame as protecting both sides at termination |
| 5 | Lift liability cap from 1 month to 12 months of purchases | MEDIUM | 12-month cap | 6-month cap is acceptable compromise |
| 6 | Adverse event reporting tightened to 5 days | LOW | 5 calendar days | Stay at 10 if pushback |
| 7 | Pharmacovigilance side-letter referencing DDA Nepal workflow | LOW | One-page side-letter | Defer to renewal cycle 2 |

---

## Obligations timeline — operational checklist

| Owner | Action | Deadline | Status |
|-------|--------|----------|--------|
| Pak Yusman (Vaksindo) | Email Agri Nutrition: "interim arrangement pending renewal" | Day 7 (by 21 May 2026) | Open |
| Pak Yusman + Dr. Teguh | Internal Nepal strategy call: Agri/Kantipur/both? | Day 14 (by 28 May 2026) | Open |
| Pak Yusman | Pull Kantipur 2024 actuals vs targets — did exclusivity convert? | Day 7 (by 21 May 2026) | Open |
| Pak Yusman | If Kantipur exclusive: send written acknowledgement-of-non-breach request to Kantipur | Day 14 (by 28 May 2026) | Open |
| Legal | Draft renewal with: single SIAC, 1266/1267 waiver, Kantipur carve-out, MA transfer-back deadline, 12-month liability cap | Day 30 (by 13 June 2026) | Open |
| Pak Yusman | Send renewal to Agri Nutrition (Suresh Vaidya) | Day 30 (by 13 June 2026) | Open |
| Both parties | Negotiate + execute renewal + new LOA | Day 60 (by 13 July 2026) | Open |
| Pak Yusman | Confirm Nepal Rastra Bank 180-day repatriation compliance for 2025–2026 USD remittances | Day 30 (by 13 June 2026) | Open |
| Pak Yusman | Pharmacovigilance side-letter — DDA Nepal reporting workflow | Day 90 (by 12 August 2026) | Open |
| Pak Yusman | Annual review of Schedule A targets — 20% uplift trigger | Q4 2026 | Future |

---

## Internal consistency check

| Item | Status |
|------|--------|
| Definitions used consistently across the contract? | Yes — minor: Art. 1.5 defines "Competing Products" with structural typo but workable |
| Cross-references match? | Yes — but Art. 22.2 referenced in Art. 24.2 reads as "Supplier reacquires" which conflicts with the actual Art. 22.2 (Supplier insurance). Looks like a numbering error; should reference Art. 24.3 (MA transfer back). Drafting issue, not commercial. |
| Schedule A products consistent with LOA? | LOA does not enumerate; Schedule A enumerates 8 SKUs. Should be enumerated in next LOA. |
| Sign-off block matches party names? | Yes |
| Effective Date populated? | Yes — 31 March 2023 |
| Signature dates populated? | **No — both party signature dates left blank**. Drafting defect (-1). |
| Page numbering complete? | Yes |
| Schedule A signed? | Yes |
| Notice clause addresses match parties' actual addresses? | Yes |

---

## Priority focus area coverage

| # | Focus area | Covered? |
|---|-----------|----------|
| 1 | Territory / location of distribution | Yes — Art. 1.14, "Nepal" |
| 2 | Exclusivity terms (and multi-distributor permissibility) | Yes — Art. 5 non-exclusive |
| 3 | Pricing & price adjustment | Yes — Art. 3 + Schedule A |
| 4 | Termination mechanics + counterparty-country mandatory termination compensation | Yes — Art. 23 + 24; no Nepal statutory exposure |
| 5 | Sales targets / minimum purchase | Yes — Art. 7 + Schedule A + Art. 18 |
| 6 | Registration / MA / NIE ownership + transfer-back | Yes — Art. 4 + 24.3-24.5 |
| 7 | Time-tiered discounts and rebates | No — silent |
| 8 | International dispute resolution and governing law — including ENFORCEABILITY | Partial — clause broken; needs fix |
| 9 | Multi-distributor strategy — can JAPFA appoint a second distributor? | YES — already done with Kantipur, need to formalize at renewal |
| 10 | Counterparty-country voidance risks (language, stamping, registration, formalities, agency-law mandatories) | Partial — Nepal Stamp Act and Nepali-language requirement not addressed; DDA Nepal addressed |

---

## Disclaimer

Advisory analysis only. Not a substitute for licensed Indonesian / Nepali legal counsel — review with internal legal before signing or acting. Findings are based on the 17-page Distribution Agreement signed 31 March 2023, the 1-page Letter of Authorization dated 27 March 2023, and cross-reference to the Kantipur Vet Distribution Agreement and LOA (Nepal). Country-specific positions verified against `references/counterparty-country-notes.md` Nepal section as of May 2026.